Guocai Zhong

Principal Investigator / Assistant Professor

University of Massachusetts Chan Medical School

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Guocai Zhong is a Principal Investigator and Assistant Professor at the University of Massachusetts Chan Medical School, United States. His research primarily focuses on the characterization of SARS-CoV-2 variants, immune evasion mechanisms, and the interaction of viral proteins with host receptors. Additionally, Dr. Zhong explores gene expression control in therapeutics and innovative approaches to vaccine development.

Articles (8)

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (1)

Devin Kenney

Boston University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Guocai Zhong

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.

Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption.

Reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire.

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo.

An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.

A more efficient CRISPR-Cas12a variant derived from <i>Lachnospiraceae bacterium</i> MA2020.

SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig

A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo

Collaborators (1)

Devin Kenney

Make your next move.